Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.75 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.37 |
| ▸ | RAD52 | P43351 | 3/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | GRK2 | P25098 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1988332 | 1.00 | GHSR (0.75) | GHSRUSP2KMT2ARAD52ESR1 | |
| SCHEMBL1989937 | 0.87 | GHSR (0.86) | GHSRUSP2KMT2ARAD52MEN1 | |
| SCHEMBL1989162 | 0.87 | GHSR (0.86) | GHSRUSP2KMT2ARAD52MEN1 | |
| SCHEMBL1990385 | 0.86 | GHSR (1.00) | GHSRUSP2KMT2ARAD52POLB | |
| SCHEMBL10122297 | 0.85 | GHSR (0.72) | GHSRUSP2KMT2ARAD52ESR1 | |
| SCHEMBL10122296 | 0.85 | GHSR (0.72) | GHSRUSP2KMT2ARAD52ESR1 | |
| SCHEMBL17631733 | 0.76 | GHSR (0.82) | GHSRMCHR1 | |
| SCHEMBL1985177 | 0.75 | GHSR (0.77) | GHSRKMT2APOLBL3MBTL3ALDH1A1 | |
| SCHEMBL1994335 | 0.75 | GHSR (0.81) | GHSRKMT2AMEN1GAA | |
| SCHEMBL1981207 | 0.75 | GHSR (0.81) | GHSRPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017075535-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20110152232-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF | SAUNDERS JEFFREY O | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152232-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF | GHSR, GHRHR, SSTR2 | GHSR 1/4885USP2 1469/4885KMT2A 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.